Wockhardt Files EMA Application for Novel Antibiotic WCK 5222

13 Jan 2026 CW Team

Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222, marking a significant milestone in the company’s global regulatory journey. The application was submitted on January 5, 2026, positioning the drug for scientific evaluation across 27 European Union member states and three European Economic Area countries—Norway, Iceland and Liechtenstein—covering a total of 30 nations.

The EMA, which is responsible for the centralised assessment of new medicines in Europe, had earlier informed Wockhardt that WCK 5222 qualifies for the Accelerated Assessment pathway. This provision enables a shortened review timeline for therapies that address serious unmet medical needs, underlining the clinical importance of the antibiotic in combating resistant infections.

WCK 5222 is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), developed to treat severe Gram-negative bacterial infections that are resistant to existing therapies. The product is already under fast-track review by the US Food and Drug Administration, reflecting growing global regulatory recognition of its potential clinical value.

Based on the clinical and regulatory data submitted, Wockhardt anticipates approval of WCK 5222 for the treatment of multidrug-resistant Gram-negative infections across all countries under the EMA’s jurisdiction. The priority status accorded to the application highlights the urgent global need for effective treatment options for patients suffering from life-threatening infections caused by antimicrobial resistance.

Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation, reinforcing India’s growing capabilities in advanced pharmaceutical research and innovation.

Real Estate

07 Jul 2026

Pecan Realty Completes Rs 1.5 Billion Transactions

Pecan Realty has recently completed four institutional transactions worth over Rs 1.5 billion over the past two years, strengthening its position as an execution-led real estate platform. The deals include resolution-led acquisitions, structured finance transactions and capital partnerships across its development portfolio.The transactions covered acquisitions through the National Company Law Tribunal process and helped provide repayment or exits to both private and public sector lenders. The company said the deals demonstrate its ability to resolve complex project situations, work with instit..

SNN Estates Expands North Bengaluru Housing Project

SNN Estates has announced an expansion of its SNN Estates Felicity residential project in North Bengaluru following strong buyer demand, with 75 per cent of the first-phase inventory sold within three days of launch.The developer will add 76 apartments in the new phase, taking the project's estimated revenue potential to around Rs 1,000 crore upon completion of Phase 2.Spread across 6.5 acres in Rachenahalli, near Manyata Tech Park, the project comprises 604 apartments in 1.5, 2, 2.5, 3 and 4 BHK configurations. The development includes a 50,000-sq-ft clubhouse with amenities such as sports co..

SCG Drives ASEAN Industrial Transformation Strategy

SCG is strengthening its focus on ASEAN as a key growth region by advancing industrial transformation, enhancing competitiveness and building resilient regional value chains. Thammasak Sethaudom, President and Chief Executive Officer, SCG, highlighted the need for industries to continuously develop capabilities, strengthen resilience and deepen regional cooperation to achieve sustainable long-term growth.SCG views ASEAN as an important growth engine alongside China, supported by favourable demographics, trade connectivity and investment flows. With ASEAN’s GDP projected to grow by around 4.7..